AstraZeneca and Abbott Partner
News May 14, 2015
AstraZeneca has announced that it has entered an agreement with Abbott, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab. To date, no companion diagnostic blood tests have been approved for use in asthma.
Under the terms of the agreement, Abbott will develop and commercialise diagnostic tests to measure serum levels of the proteins periostin and DPP4 (dipeptidyl peptidase-4), which have been identified as potential predictive biomarkers of up-regulated IL-13 in severe asthma. The tests will be developed in conjunction with AstraZeneca’s Phase III trial of tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company’s biologics research and development arm, MedImmune. Periostin has been previously described as a potential biomarker for asthma1, and DPP4 is a novel and promising predictive biomarker identified by MedImmune.
The tralokinumab Phase III programme will evaluate the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations in adults and adolescents with severe, inadequately controlled asthma despite receiving inhaled corticosteroids plus long-acting β2-agonist. The programme will also assess the effect of tralokinumab on lung function, patient-reported asthma symptoms and quality of life, as well as investigate whether serum periostin or DPP4 could identify patients who are most likely to benefit from tralokinumab.
Bing Yao, Senior Vice President and Head of MedImmune’s Respiratory, Inflammation and Autoimmunity Innovative Medicines Unit said: “This partnership with Abbott to develop companion diagnostics for tralokinumab is an important step in delivering on our ambition to bring innovative options for patients who continue to suffer with severe asthma. We anticipate that physicians will ultimately use these tests to better identify patients likely to benefit most from tralokinumab to bring their condition under control. We are on the cusp of a new era in personalised healthcare, one which will see great improvements for patients treated with respiratory medicines.”
Personalised healthcare is at the centre of AstraZeneca’s approach to drug discovery and development and this collaboration is part of the company’s strategy to seek external partners to develop companion diagnostics that will help transform patients’ lives.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE
Immune Cells Form Clots in Tumors Aiding Lung Cancer's SpreadNews
Researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018